204 related articles for article (PubMed ID: 12520482)
1. High-dose therapy and immunomodulatory drugs in multiple myeloma.
Barlogie B; Shaughnessy J; Zangari M; Tricot G
Semin Oncol; 2002 Dec; 29(6 Suppl 17):26-33. PubMed ID: 12520482
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Barlogie B
Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
[TBL] [Abstract][Full Text] [Related]
3. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
5. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
7. Treatment of myeloma in patients not eligible for transplantation.
Jagannath S
Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735
[TBL] [Abstract][Full Text] [Related]
8. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
9. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
10. Frontline treatment of multiple myeloma.
Fonseca R
Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Picot J; Cooper K; Bryant J; Clegg AJ
Health Technol Assess; 2011 Dec; 15(41):1-204. PubMed ID: 22146234
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: treatment evolution.
San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
[TBL] [Abstract][Full Text] [Related]
15. Evolving role of novel agents for maintenance therapy in myeloma.
Magarotto V; Palumbo A
Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
[TBL] [Abstract][Full Text] [Related]
16. Tandem transplants in the treatment of multiple myeloma. Pro.
Fassas AB; Tricot G
Clin Adv Hematol Oncol; 2004 May; 2(5):303-4. PubMed ID: 17682284
[No Abstract] [Full Text] [Related]
17. Therapy of relapsed and refractory multiple myeloma.
Moehler T; Goldschmidt H
Recent Results Cancer Res; 2011; 183():239-71. PubMed ID: 21509688
[TBL] [Abstract][Full Text] [Related]
18. Evolving role of stem cell transplantation in multiple myeloma.
Harousseau JL; Moreau P
Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
[TBL] [Abstract][Full Text] [Related]
19. [New treatment of multiple myeloma].
Hulin C
Rev Med Interne; 2007 Oct; 28(10):682-8. PubMed ID: 17559982
[TBL] [Abstract][Full Text] [Related]
20. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Greipp P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]